Biotechnics company Egenesis has recently announced its built -in pig kidney in a second human patient. This transplant of animal organs, or xenrancials, was made possible by progress in genes-editing and cloning.
With insufficient human kidneys to meet the demand for transplantation, egenesis and other companies aim to help close the gap with the help of Crispr-cas9technology to edit the genes that won 2020 Nobel Prize in Chemistry.
Xenorant surgery
By arranging a pig genome to remove targeted pig sequences and insert specific sequences of human DNA, Eegenesis says it can reduce the risk of organs rejection and cross -stroke infection.
“Some people have a misconception that we are editing the adult animal. We do not edit the cells, and then we can produce adult animals from the cells,” says Egenesis President and CEO Mike Curtis.
Donor animals are grown in a highly controlled environment to minimize the risk of all pathogens to take place in the object.
Curtis tells me that Eegenesis is planning several additional transplants this year to culminate in the examination of about 50 patients, after which the company hopes to have enough data to make this type of procedure more accessible.
Xenoran's recipient Tim Andrus was missed from the hospital.
As for the recipient of the Xenotransplantation Tim Andrews, he had his new kidney for about two months, and the latest word of Eegenesis is that he is doing well.
For more than our coverage of the egenesis and xenoransplants, check the video in this article.